Scribe Therapeutics
Kathleen Christie has been working in the scientific field since 2015. Kathleen began their career as a Research Assistant and PHD Student at Ulster University. In 2019, they began working as a Postdoctoral Research Fellow at both Harvard Medical School and Massachusetts General Hospital. In 2022, they will begin working as a Scientist at Scribe Therapeutics.
Kathleen Christie attended Ulster University from 2015 to 2018. Kathleen then attended Newcastle University, where they obtained a Biomedical Genetics BSc.
This person is not in the org chart
Scribe Therapeutics
1 followers
Scribe is focused on the engineering, delivery, and development of next-generation CRISPR molecules to rewrite and repair the underlying cause of genetic disorders.